It has been evaluated mainly as a cancer immunotherapy, either administered alone or as a vaccine adjuvant combined with tumor-associated antigens resulting in enhanced levels of antigen-specific CD8 T cells and reduced tumor growth [40]. The gene discussed is CD8A; the disease is neoplasm.